Therapeutic Asset Ratings

266 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Venetoclax Childhood Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2/3	B (57)
Thalidomide Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	B (56)
Benadryl B-Cell Non-Hodgkin Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (55)
Selinexor Myelodysplastic Syndrome	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (55)
Venetoclax Adult Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2/3	CCC (55)
Anti-Bcma Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (54)
FILGRASTIM Amyotrophic Lateral Sclerosis	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (54)
cd7.car/28zeta car t cells T-Lymphoblastic Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (54)
Anti-Bcma/Gprc5D Bispecific Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Avatrombopag Avatrombopag	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Azacitidine Epigenetic Repression	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Azacitidine Disease Characteristic	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Bendamustine Newly Diagnosed	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Blinatumomab Precursor Lymphoblastic Lymphoma/Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
cc-5013 Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
cd19-cart Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
cd7.car/28zeta car t cells CD7 Positive	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
CM336 Plasma Cell Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Cytosin-Arabinosid Acute Myeloid Leukemia, Biallelic CEBPA Gene Mutation	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Cytosin-Arabinosid Disease Characteristic	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Daunorubicin CEBPA Double Mutation	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Daunorubicin Disease Characteristic	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Daunorubicin Precursor Lymphoblastic Lymphoma/Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Fludarabine Newly Diagnosed	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)
Golidocitinib Cutaneous T Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (53)

Showing 101 to 125 of 266 assets

PreviousPage 5 of 11Next